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Abstract
Objective: To determine whether auditory hallucinations in community‐dwelling
people with dementia (PwD) living in the community impacted on quality of life
(QoL), subjective wellbeing and life satisfaction.
Design: Cross‐sectional cohort study.
Settings and participants: 1251 community‐dwelling PwD and caregivers were
included in this study.
Measures: Neuropsychiatric Inventory Questionnaire completed by caregiver
interview. Mean differences between the absence and presence of auditory hallu-
cinations were compared to scores on three validated measures of living well: QoL
in Alzheimer's disease scale (QoL‐AD), World Health Organization‐Five Well‐being
Index and Satisfaction with Life Scale. Analysis of covariance determined the con-
founding contributions of cognition via Mini‐Mental State Examination, depression
via Geriatric Depression Scale‐10, caregiver stress via Relative Stress Scale and
whether antipsychotic drugs were prescribed.
Results: Auditory hallucinations were associated with lower scores for QoL
(p < 0.001, η2 = 0.01), wellbeing (p < 0.001, η2 = 0.02) and life satisfaction
(p < 0.001, η2 = 0.01). After controlling for background measures, which were
potential confounds, the relationship between auditory hallucinations and QoL
(p = 0.04, pη2 = 0.01) and wellbeing (p < 0.000, pη2 = 0.02) remained significant but
there was no significant association with life satisfaction.
Conclusion: Auditory hallucinations are associated with lower QoL and wellbeing in
PwD living in the community. This has implications for targeted therapies in PwD
with psychotic symptoms.
K E Y W O R D S
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Key points
� Auditory hallucinations were significantly associated with reduced scores for quality of life
(QoL), subjective wellbeing and life satisfaction
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� The associations remained significant for QoL, wellbeing and life satisfaction after con-
trolling for cognition, depression, antipsychotic prescription, and caregiver stress
� The finding that auditory hallucinations are important for people with dementia to live well
provides a focused treatment target when developing therapies for psychotic symptoms in
people with dementia
1 | INTRODUCTION
There are 45 million people living with dementia worldwide.1 Whilst
dementia is commonly thought of as a generalized disorder of
cognition and functional impairment,2,3 neuropsychiatric symptoms
are nearly universal, and often include psychosis.4 Psychotic symp-
toms are frequently distressing to the individual and those in close
contact, including the caregiver,5 and are associated with poorer
disease outcomes, including accelerated cognitive decline,6 more
rapid progression of functional impairment,7 increased hospital ad-
missions,8 earlier admission to institutional care7 and increased
mortality.7,9 In addition, psychotic symptoms are often antecedent to
or co‐morbid with other neuropsychiatric symptoms such as agita-
tion, aggression and depression,10 further adding to the impact on
the individual and others. It is estimated that up to 50% of people
with dementia (PwD) will experience a psychotic symptom—
delusions, hallucinations or both—during the course of the disease.11
Auditory hallucinations have received far less attention than vi-
sual hallucinations or delusions, but nevertheless have a prevalence
of up to 12% in PwD, and prevalence is higher in people with Lewy
body dementia.12,13 Understanding the potential impact of auditory
hallucinations on quality of life (QoL) and elucidating their impor-
tance as a specific treatment target is therefore an important gap in
our current knowledge. QoL has been defined as describing in-
dividuals' perceptions of their position in life in the context of the
culture and value systems in which they live and in relation to their
goals, expectations, standards and concerns.14 Dementia, and symp-
toms resulting from dementia, have a key impact on a person's lived
experience and perceived QoL.15–18 Relatively few studies have
examined the impact of psychotic symptoms such as delusions and
hallucinations on QoL.19–22 The few studies that have been con-
ducted have concentrated on community‐dwelling PwD with smaller
number of participants and possibly as a consequence have generally
not identified associations between hallucinations and impaired
QoL.21,22
Whilst QoL measures have been most frequently used in evalu-
ating subjective life experience in the presence of dementia, the in-
clusion of perceived wellbeing and life satisfaction may yield a more
complete understanding of a person's ability to “live well.”23,24 Sub-
jective wellbeing represents the appropriate balance of positive and
negative emotions ascribed to one's current situation, and life satis-
faction reflects a global evaluation of one's life up to the present
circumstances.16,25 Although QoL, subjective wellbeing and life
satisfaction are interconnected, they include unique elements that
examine different facets of “living well.”16,26 Living well with chronic
illness and disability has been defined as the best achievable health
state that encompasses all dimensions of physical, mental and social
wellbeing.16,27 The specific effects of auditory hallucinations on
different facets of a person's ability to live well have not yet been
determined.
The presence of other symptoms and features of dementia may
serve as a possible confound to any interpretations associating
auditory hallucinations with living well. Symptoms commonly related
to dementia such as cognitive impairment and depression, and con-
nected features such as antipsychotic prescriptions and caregiver
stress, have been associated with lower QoL in PwD.15,17,18,26,28,29 It
is important to delineate the contributions of these factors when
assessing the impact of psychotic symptoms in dementia.
The primary aim of this study was to determine the impact of
auditory hallucinations on living well in PwD living in the community.
We also aimed to elucidate the role of various possible confounds,
such as depression, cognition, whether antipsychotic drugs were
prescribed and caregiver stress, when evaluating the impact of
auditory hallucinations on these outcomes.
2 | METHODS
2.1 | Study population
The study used data from the Improving the experience of Dementia
and Enhancing Active Life (IDEAL) study, a longitudinal cohort study
conducted across England, Scotland and Wales to investigate social,
psychological and economic factors that may enhance the capacity to
“live well” with dementia.26,29 The IDEAL cohort at baseline
comprised 1540 community‐dwelling PwD and 1278 caregivers
recruited between June 2014 and August 2016 through a network of
29 National Health Service sites. The present study used cross‐
sectional data from the IDEAL baseline assessment and the analysis
was conducted on version 4.5 of the dataset.
All PwD had a clinical diagnosis of dementia and were in the
mild‐to‐moderate stages as indicated by a Mini‐Mental State Ex-
amination (MMSE)30 score of 15 or above on entry to the study.
For each person with dementia a family member or friend, subse-
quently referred to as a caregiver, who provided practical or
emotional unpaid support was also invited to take part where
available and willing. Informed consent was obtained from all PwD
and caregivers. Researchers visited PwD and their caregivers in
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their homes to conduct structured interviews. The caregivers were
asked to complete questionnaires separately, and both acted as
informants regarding the person with dementia and provided in-
formation about their own experiences. Data from PwD were
included in the present study only if there was an accompanying
caregiver to form a participant dyad and if the caregiver answered
the question on auditory hallucinations from the Neuropsychiatric
Inventory Questionnaire (NPI‐Q).31,32
The IDEAL study was approved by the Wales 5 Research Ethics
Committee (reference:13/WA/0405) and the Ethics Committee of
the School of Psychology, Bangor University (reference 2014—
11684). The IDEAL study is registered with the UK Clinical Research
Network, registration number 16593.
2.2 | Measures
Auditory hallucinations: Caregivers completed the NPI‐Q and were
asked whether the person with dementia was experiencing symp-
toms in 12 discrete behavioral domains.31 For the purpose of the
present study, we only used the domain for auditory hallucinations.
Specifically, presence of auditory hallucinations was defined as a
caregiver's positive response to the question “Does your relative/
friend act as if s/he hears voices? Does s/he talk to people who are
not there?”32
Living well: Three self‐report measures were completed by PwD
to assess living well with dementia. These were the QoL in Alz-
heimer's disease scale (QoL‐AD)33 total score, the World Health
Organization‐Five Well‐Being Index (WHO‐5)34,35 percentage score,
and Satisfaction with Life Scale (SwLS)25 total score. For each mea-
sure, a higher score indicates greater capability to “live well”; QoL‐
AD range 13–52, WHO‐5 range 0‐100, and SwLS range 5–35. For
convenience the three measures together will be referred to as
“living well” measures.
Cognition, mood and caregiver stress: The following additional
measures from IDEAL were included in this analysis. The MMSE was
used to measure cognition in PwD, with higher scores indicative of
better cognition.30 The Geriatric Depression Scale‐10 (GDS‐10) was
used to measure depression in PwD, with higher scores indicating
more self‐rated depressive symptoms.36 The Relative Stress Scale
(RSS) measured the level of self‐reported caregiver stress; possible
scores range from 0 to 60 with higher scores indicating greater
caregiver stress.37
Demographic data: Information on age and sex were obtained
from PwD and caregivers. Additionally, information on education was
obtained from PwD. Dementia diagnosis was provided by researchers
from medical notes. Information about whether antipsychotic drugs
were prescribed was obtained from a joint interview with the dyad
using a pre‐defined list of medications. Educational level was classi-
fied into four groups: no qualifications; school leaving certificate at
age 16; school leaving certificate at age 18; university. Relationship
with the participant was classified into two groups: spouse/partner
and other. Whether antipsychotic drugs were prescribed was coded
as a binary yes/no variable.
2.3 | Planned analyses
All statistical analyses were carried out using SPSS Statistics v26.
The main analyses used ANOVA to compare mean scores on
measures of living well reported by those experiencing and not
experiencing auditory hallucinations. Having conducted analyses on
the three living well measures, a Bonferroni‐adjusted alpha was
used to correct for multiple comparisons; therefore, a p‐value equal
to/less than 0.016 was required to reach statistical significance. If a
significant effect was found in the main analyses, further analyses
were conducted using analysis of covariance (ANCOVA) to examine
the confounding effect of cognition, depression, whether antipsy-
chotic drugs were prescribed and caregiver stress on the associa-
tion of the presence or absence of auditory hallucinations with
living well. Effect size was calculated using eta squared (η2) for
ANOVA and partial eta squared (pη2) for ANCOVA. Effect sizes
were interpreted as follows; small (0.01 to 0.05), moderate (0.06 to
0.13), or large (≥0.14).38
3 | RESULTS
Among the 1278 eligible participant dyads, 27 caregivers did not
answer the relevant question on auditory hallucination in the NPI‐Q;
hence the total number of dyads included in the analysis was 1251.
Slightly more than half of the PwD were men (736%, 58.8%), with
Alzheimer's disease (697%, 55.7%) being the most common diagnosis.
Relatively few were prescribed antipsychotic drugs (26%, 2.1%).
Prevalence of auditory hallucinations by dementia subtype was:
Alzheimer's disease (n = 37) 5.3%; vascular dementia (n = 5) 3.6%:
mixed Alzheimer's disease and vascular dementia (n = 17) 6.6%; ,
frontotemporal dementia (n = 3) 6.8%; Parkinson's disease dementia
(n = 13) 31.0%; dementia with Lewy bodies (n = 20) 47.6%; and
unspecified/other (n = 2) 6.5%. The sample characteristics are sum-
marized in Table 1.
3.1 | Impact of auditory hallucination on living well
The first research question focused on whether there was an asso-
ciation between the presence of informant‐rated auditory halluci-
nations and living well in PwD. Auditory hallucinations were
significantly associated with lower scores for QoL, WHO‐5, and
SwLS, although effect sizes were small; see Table 2.
The second research question asked whether the difference
between informant‐rated auditory hallucinations and living well
could be explained by cognition, depression, whether antipsychotic
drugs were prescribed, or caregiver stress. ANCOVA suggested
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T A B L E 1 Characteristics of people
with dementia and caregivers
Demographic information n (%)
Characteristics of people with dementia 1251
Sex Male 736 (58.8)
Female 515 (41.2)





Education No qualifications 327 (26.1)
School leaving certificate at age 16 222 (17.7)
School leaving certificate at age 18 427 (34.1)
University 244 (19.5)
Missing 31 (2.5)
Dementia diagnosis Alzheimer's disease 697 (55.7)
Vascular dementia 139 (11.1)
Mixed (Alzheimer's and vascular) 256 (20.5)
Frontotemporal dementia 44 (3.5)
Parkinson's disease dementia 42 (3.4)
Dementia with Lewy bodies 42 (3.4)
Unspecified/other dementia 31 (2.5)
Auditory hallucinationsa No 1155 (92.3)
Yes 97 (7.7)
Antipsychotic medication No 1226 (98.0)
Yes 26 (2.0)
Mean (SD); n
Mini‐Mental State Examination 23.1 (3.7); 1187
Geriatric Depression Scale‐10 2.7 (2.3); 1127
Quality of life in Alzheimer's disease 36.9 (5.9); 1139
World Health Organization‐Five Well‐Being Index 61.4 (20.5); 1228
Satisfaction with Life Scale 26.5 (5.9); 1217
Characteristics of caregivers n (%)
Sex Male 386 (30.9)
Female 865 (69.1)





Relationship to person with dementia Spouse/partner 1018 (81.4)
Other family/friend 216 (17.2)
Missing 17 (1.4)
Mean (SD); n
Relative Stress Scale 19.2 (9.8); 1187
aSymptoms indicated by caregiver via the Neuropsychiatric Inventory‐Questionnaire.
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that for QoL‐AD scores the main effect of auditory hallucinations
remained statistically significant after controlling for a priori con-
founding variables, but effect sizes were small; see Table 3.
ANCOVA also indicated that for WHO‐5 scores the association
between auditory hallucination and wellbeing remained statistically
significant. The ANCOVA did not find a statistically significant
main effect of auditory hallucinations on life satisfaction scores.
The results show that the association between auditory halluci-
nations and reduced QoL and wellbeing remained significant after
controlling for a priori covariates but not life satisfaction.
Depression was a significant confounding variable with large effect
sizes.
4 | DISCUSSION
The present study examined the associations of auditory halluci-
nations with self‐reported QoL, wellbeing and life satisfaction in
community‐dwelling PwD. To our knowledge, this is the first study
to use data from a large cohort to examine the relationship be-
tween auditory hallucinations and living well in community‐dwelling
PwD. Auditory hallucinations were associated with significantly
lower scores on measures of living well, and these findings
remained significant for QoL and wellbeing measures after adjusting
for cognitive impairment, depression, antipsychotic usage and
caregiver stress, confounding factors known to affect QoL in
PwD.15,17,18,28,29 The prevalence of auditory hallucinations in this
cohort (7.7%) was similar to that found in previous literature11,13
which suggests that prevalence of auditory hallucinations in
community‐dwelling people with mild‐to‐moderate dementia is
likely to be around 10%. We found prevalence to be higher in PwD
with Lewy bodies and Parkinson's disease dementia, which is
consistent with previous research.12,13
No significant associations were detected for prescribed anti-
psychotics or cognitive impairment. Importantly, relatively few PwD
in this cohort were prescribed antipsychotic medication (2.1%) as
compared to previous studies that had detected an association be-
tween poor QoL and antipsychotic prescription,15,19 and therefore
the statistical power to detect associations with antipsychotic usage
was low. Caregiver stress had a small effect on QoL for the person
with dementia, but not wellbeing and life satisfaction, which is
consistent with previous literature where caregiver stress has a
stronger association with informant‐rated living well rather than self‐
rated living well in PwD.17
As highlighted in previous literature, depression is a frequent co‐
morbidity in PwD with psychosis.10 In the current study it was a key
covariate alongside auditory hallucinations and associated with lower
QoL, wellbeing and life satisfaction in PwD. Furthermore, depression
had the largest effect size on all three living well measures of any of
the co‐variates. This result aligns with previous studies, in which
depression has been a common predictor of poor QoL.15,17,18,28,29
Importantly, the large effect size of depression detected in our
analysis along with evidence from previous literature may indicate a
potential association chain with depression having substantial
T A B L E 2 Relationship between auditory hallucinations and scores on measures of living well
Auditory hallucinations No auditory hallucinations
F statistic p Effect sizeMean (SD); n Mean (SD); n
Quality of Life in Alzheimer's Disease scale 34.57 (6.10), 83 37.12 (5.87), 1056 (1,1137) = 14.44 <0.001 0.013
World Health Organization‐Five Well‐Being Index 52.34 (20.07), 94 62.21 (20.40), 1134 (1,1226) = 20.39 <0.001 0.016
Satisfaction with Life Scale 24.61 (6.50), 95 26.71 (5.82), 1122 (1,1215) = 11.13 <0.001 0.009
T A B L E 3 Relationship between auditory hallucinations and
scores on measures of living well adjusted for covariates
Covariate Df F statistic p Effect size
Quality of Life in Alzheimer's Disease scale
Antipsychotic medication 1 0.47 0.495 0.000
Cognition 1 0.99 0.411 0.001
Caregiver stress 1 9.91 0.002 0.010
Depression 1 747.03 <0.001 0.440
Auditory hallucinations 1 4.12 0.043 0.004
Error 952
R2 = 0.473 (adjusted R2 = 0.470)
World Health Organization‐Five Well‐Being Index
Antipsychotic medication 1 2.97 0.085 0.003
Cognition 1 4.23 0.040 0.004
Caregiver stress 1 1.08 0.299 0.001
Depression 1 645.66 <0.001 0.390
Auditory hallucinations 1 16.46 <0.001 0.016
Error 1008
R2 = 0.409 (adjusted R2 = 0.406)
Satisfaction with Life Scale
Antipsychotic medication 1 0.26 0.610 0.000
Cognition 1 1.49 0.221 0.001
Caregiver stress 1 3.84 0.050 0.004
Depression 1 384.53 <0.001 0.277
Auditory hallucinations 1 3.00 0.084 0.003
Error 1002
R2 = 0.302 (adjusted R2 = 0.299)
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influence on reduced QoL, and limits interpretations of the rela-
tionship between auditory hallucinations and QoL.
The main strengths of the present study are the novel focus on
auditory hallucinations, the breadth of measurement covering not
just QoL but also wellbeing and life satisfaction, and the size of the
cohort which gives good statistical power to examine the associations
with living well. Additionally, the use of self‐reported outcome
measures in this study provides direct insight into the perspectives of
PwD regarding their perception of living well. The study was limited
by the slight reduction in sample size in the ANCOVA due to missing
data, and the unavailability of NPI‐Q data in a small number of cases,
although the sample was still much larger than in previous studies.
Small numbers of participants with rarer types of dementia reduced
our ability to further investigate the effects of auditory hallucinations
among people with these diagnoses. Additionally, the cross‐sectional
nature of the study restricted any causal interpretation, although this
will be addressed once longitudinal data are available.
An important implication of these findings is to identify auditory
hallucinations as an important treatment target in community‐
dwelling PwD. Given the potentially harmful effects of antipsy-
chotic drugs,39 the development of effective psychological therapies
for key psychotic symptoms that include auditory hallucinations in
PwD should be a priority. Importantly, our findings indicate that
auditory hallucinations significantly impact the QoL and wellbeing of
PwD living in the community, and therefore represent a key treat-
ment target. Of note, there are a number of evidence‐based psy-
chological therapies for people with schizophrenia and auditory
hallucinations40 which could potentially be adapted to treat these
symptoms in PwD.
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